Moreover, MSI patients with wild-type KRAS and BRAF tumors have more favorable prognosis than patients with mutated KRAS or BRAF tumors in early stage CRC (De Cuba et al., 2016; Phipps et al., 2015). The gene discussed is KRAS; the disease is colorectal carcinoma.